Published in J Cardiovasc Pharmacol Ther on December 01, 2005
Direct thrombin inhibitors in cardiovascular disease. Nat Rev Cardiol (2012) 0.77
Bivalirudin in percutaneous coronary intervention. Vasc Health Risk Manag (2006) 0.76
The Use of Heparin during Endovascular Peripheral Arterial Interventions: A Synopsis. Scientifica (Cairo) (2016) 0.75
Pharmacological prevention of peri-, and post-procedural myocardial injury in percutaneous coronary intervention. Curr Cardiol Rev (2008) 0.75
Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis. Medicine (Baltimore) (2015) 0.75
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Assessing the impact of population stratification on genetic association studies. Nat Genet (2004) 16.28
Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med (2012) 13.59
Human genetic variation and its contribution to complex traits. Nat Rev Genet (2009) 12.11
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66
Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol (2009) 9.59
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med (2011) 6.90
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85
Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev (2009) 6.85
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol (2011) 6.35
9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature (2011) 6.25
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol (2003) 5.51
Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet (2003) 5.34
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet (2004) 5.31
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol (2009) 4.80
Can mobile health technologies transform health care? JAMA (2013) 4.75
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet (2005) 4.45
Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 4.30
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA (2005) 4.23
Pathway analysis of seven common diseases assessed by genome-wide association. Genomics (2008) 4.11
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med (2010) 3.79
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64
Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med (2011) 3.52
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 3.38
Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science (2003) 3.34
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA (2007) 3.25
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med (2010) 3.17
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol (2004) 2.97
Characterization of circulating endothelial cells in acute myocardial infarction. Sci Transl Med (2012) 2.91
Arthritis medicines and cardiovascular events--"house of coxibs". JAMA (2004) 2.89
Accurate detection and genotyping of SNPs utilizing population sequencing data. Genome Res (2010) 2.84
Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J (2005) 2.80
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.69
Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61
Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.56
Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation (2004) 2.54
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med (2009) 2.52
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol (2007) 2.47
Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation (2009) 2.47
International differences in evolution of early discharge after acute myocardial infarction. Lancet (2004) 2.47
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47
The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med (2011) 2.43
2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2012) 2.40
Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. Am J Hum Genet (2004) 2.36
Enrichment of sequencing targets from the human genome by solution hybridization. Genome Biol (2009) 2.32
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA (2005) 2.26
The importance of phase information for human genomics. Nat Rev Genet (2011) 2.25
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke (2004) 2.24
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.24
Consumer perceptions of direct-to-consumer personalized genomic risk assessments. Genet Med (2010) 2.23
The case for routine genotyping in dual-antiplatelet therapy. J Am Coll Cardiol (2010) 2.19